

General information about company	
Scrip code*	000000
NSE Symbol*	MADHAVBAUG
MSEI Symbol*	NOTLISTED
ISIN*	INE0JR301013
Name of company	VAIDYA SANE AYURVED LABORATORIES LIMITED
Type of company	SME
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	05-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	30-10-2025
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Half Yearly
Reporting Quarter	Half yearly
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	
Segment Reporting	Multi segment
Description of single segment	
Start date and time of board meeting	05-11-2025 11:30
End date and time of board meeting	05-11-2025 13:20
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	

Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?		Yes
Latest Date on which RPT policy is updated		22-05-2025
Indicate Company website link for updated RPT policy of the Company		https://madhavbaug.org/policies-and-code-of-conduct/
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?		Yes
No. of times funds raised during the quarter		2
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	Not Applicable

Financial Results – Other than Bank				
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
Date of start of reporting period		01-04-2025	01-04-2025	
Date of end of reporting period		30-09-2025	30-09-2025	
Whether results are audited or unaudited		Unaudited	Unaudited	
Nature of report standalone or consolidated		Standalone	Standalone	
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.			
1	Revenue From Operations			
	Revenue from operations	4718.57	4718.57	
	Other income	96.66	96.66	
	Total Income	4815.23	4815.23	
2	Expenses			
(a)	Cost of materials consumed	0	0	
(b)	Purchases of stock-in-trade	1290.21	1290.21	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0	0	
(d)	Employee benefit expense	865.79	865.79	
(e)	Finance costs	7.06	7.06	
(f)	Depreciation and amortisation expense	273.76	273.76	
(g)	Other Expenses			
1	Other Expenses	1949.79	1949.79	
	Total other expenses	1949.79	1949.79	
	Total expenses	4386.61	4386.61	
3	Profit before exceptional and extraordinary items and tax	428.62	428.62	
4	Exceptional items	0	0	
5	Profit before extraordinary items and tax	428.62	428.62	
6	Extraordinary items	0	0	
7	Profit before tax	428.62	428.62	
8	Tax Expense			
	Current tax	129.29	129.29	
	Deferred tax	-23.06	-23.06	
	Total tax expenses	106.23	106.23	
9	Net Profit Loss for the period from continuing operations	322.39	322.39	

10	Profit (loss) from discontinuing operations before tax	0	0	
11	Tax expense of discontinuing operations	0	0	
12	Net profit (loss) from discontinuing operation after tax	0	0	
13	Profit (loss) for period before minority interest	322.39	322.39	
14	Share of profit (loss) of associates			
15	Profit (loss) of minority interest			
16	Net profit (Loss) for the period	322.39	322.39	
17	Details of equity share capital			
	Paid-up equity share capital	1051.35	1051.35	
	Face value of equity share capital	10	10	
	Details of debt securities			
18	Reserves excluding revaluation reserve			
19	Earnings per equity share (for continuing and discontinued operations)			
	Basic earnings (loss) per share from continuing and discontinued operations	3.07	3.07	
	Diluted earnings (loss) per share from continuing and discontinued operations	3.07	3.07	
20	Debt equity ratio			Textual Information(1)
21	Debt service coverage ratio			Textual Information(2)
22	Interest service coverage ratio			Textual Information(3)
23	Disclosure of notes on financial results			

Statement of Asset and Liabilities		
	Particulars	Half Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2025
	Date of end of reporting period	30-09-2025
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
	Equity and liabilities	
1	Shareholders' funds	
	Share capital	1051.35
	Reserves and surplus	5241.11
	Money received against share warrants	
	Total shareholders' funds	6292.46
2	Share application money pending allotment	0
3	Deferred government grants	
4	Minority interest	
5	Non-current liabilities	
	Long-term borrowings	0
	Deferred tax liabilities (net)	0
	Foreign currency monetary item translation difference liability account	0
	Other long-term liabilities	134.32
	Long-term provisions	172.42
	Total non-current liabilities	306.74
6	Current liabilities	
	Short-term borrowings	63.07
	Trade Payables	
	(A) Total outstanding dues of micro enterprises and small enterprises	39.14
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	512.56
	Total Trade payable	551.7
	Other current liabilities	272.92
	Short-term provisions	74.73
	Total current liabilities	962.42
	Total equity and liabilities	7561.62
	Assets	
1	Non-current assets	
(i)	Property, Plant and Equipment and Intangible assets	
	Property, Plant and Equipment	1863.12
	Producing properties	0

	Intangible assets	733.01
	Preproducing properties	0
	Property, Plant and Equipment capital work-in-progress	33.2
	Intangible assets under development or work-in-progress	127.73
	Total Property, Plant and Equipment and Intangible assets	2757.06
(ii)	Non-current investments	1645.02
(v)	Deferred tax assets (net)	3.74
(vi)	Foreign currency monetary item translation difference asset account	0
(vii)	Long-term loans and advances	724.2
(viii)	Other non-current assets	0
	Total non-current assets	5130.02
2	Current assets	
	Current investments	932.94
	Inventories	165.12
	Trade receivables	575.4
	Cash and cash equivalents	513.51
	Bank balance other than cash and cash equivalents	0
	Short-term loans and advances	244.63
	Other current assets	0
	Total current assets	2431.6
	Total assets	7561.62

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025	01-04-2025
Date of end of reporting period		30-09-2025	30-09-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Standalone	Standalone
1 Segment Revenue			
(net sale/income from each segment should be disclosed)			
1	Hospital Activity	1290.19	1290.19
2	Sale of Product Activity	3117.59	3117.59
3	Common/unallocable	310.79	310.79
	Total segment revenue	4718.57	4718.57
	Less: Inter segment revenue	0	0
	Revenue from operations	4718.57	4718.57
2 Segment Result			
Profit (+) / Loss (-) before tax and interest from each segment			
1	Hospital Activity	659.11	659.11
2	Sale of Product Activity	1205.89	1205.89
3	Common/unallocable	2344.49	2344.49
	Total Profit before tax	4209.49	4209.49
	i. Finance cost	-380	-380
	ii. Other unallocable expenditure net off unallocable income	0	0
	Profit before tax	4589.49	4589.49
3 (Segment Asset - Segment Liabilities)			
Segment Asset			
1	Hospital Activity	1866.7	1866.7
2	Sale of Product Activity	0	0
3	Common/unallocable	0	0
	Total Segment Assets	1866.7	1866.7
	Un-allocable Assets	5694.91	5694.91
	Net Segment Assets	7561.61	7561.61
4 Segment Liabilities			
Segment Liabilities			
1	Hospital Activity	16.81	16.81
2	Sale of Product Activity	0	0

3	Common/unallocable	0	0
	Total Segment Liabilities	16.81	16.81
	Un-allocable Liabilities	7544.8	7544.8
	Net Segment Liabilities	7561.61	7561.61

Cash flow statement - indirect	
Particulars	Half Year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2025
Date of end of reporting period	30-09-2025
Whether results are audited or unaudited	Unaudited
Nature of report standalone or consolidated	Standalone
1 Statement of cash flows	
Cash flows from used in operating activities	
Profit before extraordinary items and tax	428.62
2 Adjustments for reconcile profit (loss)	
Adjustments to profit (loss)	
Adjustments for finance costs	-66.76
Adjustments for depreciation and amortisation expense	273.76
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
Adjustments for unrealised foreign exchange losses gains	0
Adjustments for dividend income	0
Adjustments for share-based payments	0
Other adjustments for which cash effects are investing or financing cash flow	0
Other adjustments to reconcile profit (loss)	0
Other adjustments for non-cash items	5.86
Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
Total adjustments to profit (loss)	212.86
3 Adjustments for working capital	
Adjustments for decrease (increase) in inventories	37.18
Adjustments for decrease (increase) in trade receivables	127.9
Adjustments for decrease (increase) in other current assets	-183.98
Adjustments for increase (decrease) in trade payables	-173.56
Adjustments for increase (decrease) in other current liabilities	123.21
Adjustments for provisions	8.93
Total adjustments for working capital	-60.32
Total adjustments for reconcile profit (loss)	152.54
Net cash flows from (used in) operations	581.16
Dividends received	0
Interest paid	0
Interest received	0
Income taxes paid (refund)	129.29
Other inflows (outflows) of cash	0

	Net cash flows from (used in) operating activities before extraordinary items	451.87
	Proceeds from extraordinary items	0
	Payment for extraordinary items	0
	Net cash flows from (used in) operating activities	451.87
4	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property plant and equipment	0.95
	Purchase of property plant and equipment	207.83
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	66.76
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	59.7
	Proceeds from government grants	0
	Net cash flows from (used in) investing activities before extraordinary items	-80.42
	Proceeds from extraordinary items	0
	Payment for extraordinary items	0
	Net cash flows from (used in) investing activities	-80.42
5	Cash flows from used in financing activities	
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	0
	Repayments of borrowings	82.93
	Dividends paid	0
	Interest paid	7.06

	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) financing activities before extraordinary items	-89.99
	Proceeds from extraordinary items	0
	Payment for extraordinary items	0
	Net cash flows from (used in) financing activities	-89.99
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	281.46
6	Effect of exchange rate changes on cash and cash equivalents	
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	281.46
	Cash and cash equivalents cash flow statement at beginning of period	232.05
	Cash and cash equivalents cash flow statement at end of period	513.51

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 3rd)															
															tr list
Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		Ir in
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	
1	Vaidya Sane Ayurved Laboratories Ltd	AABCV7806M	Dr. Rohit Madhav Sane	APCPS4491J	Pramoter, MD and CEO	Any other transaction	Rent	3675359	NA			3675359	0	0	
2	Vaidya Sane Ayurved Laboratories Ltd	AABCV7806M	Dr. Rohit Madhav Sane	APCPS4491J	Pramoter, MD and CEO	Sale of goods or services		1113075	NA			1113075	101999	162162	
3	Vaidya Sane Ayurved Laboratories Ltd	AABCV7806M	Dr. Rohit Madhav Sane	APCPS4491J	Pramoter, MD and CEO	Remuneration		3000000	NA			3000000	242300	-8900	
4	Vaidya Sane Ayurved Laboratories Ltd	AABCV7806M	Dr. Vidyut Bipin Ghag	AWHPK6600M	Independent Director	Remuneration		1180000	NA			1180000	0	0	
5	Vaidya Sane Ayurved Laboratories Ltd	AABCV7806M	Mr. Narendra Pawar	AGQPP1877N	Chief Financial Officer	Remuneration		1069500	NA			1069500	0	0	
6	Vaidya Sane Ayurved Laboratories Ltd	AABCV7806M	Mr. Narendra Pawar	AGQPP1877N	Chief Financial Officer	Loan		0	NA			0	0	258000	
7	Vaidya Sane Ayurved Laboratories Ltd	AABCV7806M	Ms. Sapna Vaishnav	AYXPV9916D	Company Secretary	Remuneration		665886	NA			665886	0	0	
8	Vaidya Sane Ayurved Laboratories Ltd	AABCV7806M	Mr. Yogesh Walawalkar	AADPW3216B	Senior VP Marketing	Remuneration		483720	NA			483720	0	0	
9	Vaidya Sane Ayurved Laboratories Ltd	AABCV7806M	Dr. Gurudatta Amin	ASNPA0016B	Chief Medical Officer	Remuneration		1700004	NA			1700004	0	0	

10	Vaidya Sane Ayurved Laboratoies Limited	AABCV7806M	Aaharshastra Foodz Private Limited	AAZCA3488L	Associate Company	Interest received		79817	NA			79817	6543	94910	
11	Vaidya Sane Ayurved Laboratoies Limited	AABCV7806M	Aaharshastra Foodz Private Limited	AAZCA3488L	Associate Company	Any other transaction	Professional Fees paid	4000	NA			4000	0	0	
12	Vaidya Sane Ayurved Laboratoies Limited	AABCV7806M	Dynamic Remedies Private Limited	AABCD7351H	Subsidiary Company	Purchase of goods or services		75382976	NA			75382976	-18123699	-15374738	
13	Vaidya Sane Ayurved Laboratoies Limited	AABCV7806M	U V Ayruugen Private Limited	AABCU0693B	Subsidiary Company	Purchase of goods or services		44271837.98	NA			44271837.98	-5214780	-1541238	
14	Vaidya Sane Ayurved Laboratories Ltd	AABCV7806M	Vd Sane Ayurvedic Edu. & Agr. Res. Trust	AAATV4929R	Entity Controlled by Pramotor	Sale of goods or services		57545754	NA			57545754	27796557	27501375	
15	Vaidya Sane Ayurved Laboratories Ltd	AABCV7806M	Medemy Life Science Private Ltd	AANCM7034J	Entity Controlled by Pramotor	Sale of goods or services		21487085	NA			21487085	7720273	-1836352	
16	Vaidya Sane Ayurved Laboratories Ltd	AABCV7806M	Medemy Life Science Private Ltd	AANCM7034J	Entity Controlled by Pramotor	Any other transaction	rent	708000	NA			708000	108000	108000	
17	Vaidya Sane Ayurved Laboratories Ltd	AABCV7806M	Easy Ayurveda Private Limtied	AAHCE2881K	Associate Company	Interest received		1552340	NA			1552340	3213514	4765854	
18	Vaidya Sane Ayurved Laboratories Ltd	AABCV7806M	Gurudatta Enterprises	AASFG5296L	Relative of KMP is partner	Sale of goods or services		1647533	NA			1647533	838741	329805	
19	U V Ayruugen Private Limited	AABCU0693B	Vaidya Sane Ayurved Laboratories Ltd	AABCV7806M	Holding Company	Sale of goods or services		44271837.98	NA			44271837.98	5214780	1541238	
20	U V Ayruugen Private Limited	AABCU0693B	Parikshit Bhide	BHXPB2999E	Director	Remuneration		600000	NA			600000	0	0	
21	U V Ayruugen Private Limited	AABCU0693B	Sonali Patil	CIOPP5956N	Spouse of Director	Any other transaction	Professional Fees	24000	NA			24000	0	0	
22	U V Ayruugen Private Limited	AABCU0693B	Pradip Patil	CDOPP4589E	Director	Any other transaction	Expenses Reimbursement	303500	NA			303500	0	0	
23	U V Ayruugen Private Limited	AABCU0693B	Aaharshastra Foodz Private Limited	AAZCA3488L	Associate Company of Holding Company	Any other transaction	Professional Fees paid	52500	NA			52500	0	0	

24	U V Ayrugen Private Limited	AABCU0693B	Dynamic Remedies Private Limited	AABCD7351H	Having control of Same Holding Company	Sale of goods or services		11091308.43	NA			11091308.43	906468	1907889	
25	U V Ayrugen Private Limited	AABCU0693B	Dynamic Remedies Private Limited	AABCD7351H	Having control of Same Holding Company	Sale of goods or services		1627274.32	NA			1627274.32	212804	290842	
26	U V Ayrugen Private Limited	AABCU0693B	Dynamic Remedies Private Limited	AABCD7351H	Having control of Same Holding Company	Inter- corporate deposit		305507	NA			305507	170876	476383	
27	U V Ayrugen Private Limited	AABCU0693B	Dynamic Remedies Private Limited	AABCD7351H	Having control of Same Holding Company	Any other transaction	Loans/Inter corporate Deposit	0	NA			0	5000000	0	
28	Dynamic Remedies Private Limited	AABCD7351H	Vaidya Sane Ayurved Laboratories Ltd	AABCV7806M	Holding Company	Sale of goods or services		75382976	NA			75382976	18123699	15374738	
29	Dynamic Remedies Private Limited	AABCD7351H	U V ayrugen Private Limited	AABCU0693B	Having control of Same Holding Company	Sale of goods or services		11091308.43	NA			11091308.43	906468	1907889	
30	Dynamic Remedies Private Limited	AABCD7351H	U V ayrugen Private Limited	AABCU0693B	Having control of Same Holding Company	Sale of goods or services		1627274.32	NA			1627274.32	212804	290842	
31	Dynamic Remedies Private Limited	AABCD7351H	U V ayrugen Private Limited	AABCU0693B	Having control of Same Holding Company	Interest received		305507	NA			305507	-170876	-476383	
32	Dynamic Remedies Private Limited	AABCD7351H	U V ayrugen Private Limited	AABCU0693B	Having control of Same Holding Company	Any other transaction	Loans/Inter corporate Deposit	0	NA			0	-5000000	0	
33	Dynamic Remedies Private Limited	AABCD7351H	Kiran Bhide	ADQPB9227R	Director	Remuneration		1500000	NA			1500000	0	0	
34	Dynamic Remedies Private Limited	AABCD7351H	Kiran Bhide	ADQPB9227R	Director	Any other transaction	Expenses Reimbursement	671	NA			671	0	0	
35	Dynamic Remedies Private Limited	AABCD7351H	Dr Gurudatta Amin	ASNPA0016B	Director	Remuneration		225000	NA			225000	0	0	
36	Dynamic Remedies	AABCD7351H	Madura Bhide	ABTPB8040R	Relative of Pramoter of	Sale of goods or services		21216	NA			21216	5427	12822	

	Private Limited				Holding Company										
37	Dynamic Remedies Private Limited	AABCD7351H	Dr Rekha Paralkar	AGVPP2789E	Relative of Pramoter of Holding Company	Sale of goods or services		50946	NA			50946	3057	11900	
38	Dynamic Remedies Private Limited	AABCD7351H	Dr. Rohit Sane	APCPS4491J	Managing Director of Holding Company	Sale of goods or services		33442	NA			33442	6851	21490	
39	Aaharshastra Foodz Private Limited	AAZCA3488L	Vaidya Sane Ayurved Laboratoies Limited	AABCV7806M	Associate Company	Interest paid		79817	NA			79817	-6543	-94910	
40	Aaharshastra Foodz Private Limited	AAZCA3488L	Vaidya Sane Ayurved Laboratoies Limited	AABCV7806M	Associate Company	Any other transaction	Professional Fees paid	4000	NA			4000	0	0	
41	Aaharshastra Foodz Private Limited	AAZCA3488L	U V Ayrugen Private Limited	AABCU0693B	Associate Company of Holding Company	Any other transaction	Professional Fees paid	52500	NA			52500	0	0	
Total value of transaction during the reporting period												364217472.46			

Details of Impact of Audit Qualification			
Whether results are audited or unaudited		Unaudited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	A A Mohare & Co	Yes	31-12-2027

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)	
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	27-05-2024
Amount Raised	27668750
Report filed for Quarter ended	30-09-2025
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	
Comments of the Audit Committee after review	None- reviewed by the Audit Committee at its Meeting held on 05th november, 2025
Comments of the auditors, if any	None

Signatory Details	
Name of signatory	Rohit Sane
Designation of person	Managing Director
Place	Rohit Sane
Date	05-11-2025

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (2)	
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	14-08-2023
Amount Raised	106644600
Report filed for Quarter ended	30-09-2025
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	
Comments of the Audit Committee after review	None- reviewed by the Audit Committee at its Meeting held on 05th november, 2025
Comments of the auditors, if any	None

